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Abstract 
The emergence of liver diseases as one of the major causes of death in people infected with HIV has 
paralleled the introduction of more effective antiretroviral therapies. This study was carried out with the aim 
of determining the effects of antiretroviral treatment on liver enzymes (SGOT and SGPT) in patients placed 
on antiretroviral therapy. A prospective cross-sectional 3 years study was carried out among patients 
confirmed to be HIV positive and who were to be placed on antiretroviral drugs at the HIV/AIDS out patient 
clinic of the Yaoundé Central Hospital, . Cameroon. Levels of transaminases of patients were measured in four 
phases using the International Federation of Clinical Chemistry (IFCC) protocol. Of the 150 patients who 
participated in the study, 54.0 %( 81/150) presented with transaminitis at the final phase of the study with 
respect to aspartate aminotransferase (AST), 77.78% (63/81) of whose AST levels only increased after initiation 
of highly active antiretroviral therapy (HAART). 22.67% (34/150) presented with transaminitis with respect to 
alanine aminotransferase (ALT). At the final phase, 70.58% of whose ALT levels only increased after HAART 
initiation. Increase in blood transaminase levels was statistically independent on age group and the drug 
combinations. Increase in AST levels was associated with an increase in ALT levels upon treatment (r = 0.58).  
There was a significant positive linear relationship between duration of treatment and concentration of 
transaminases over the years (r= 0.9). We therefore concluded that highly active antiretroviral therapy 
(HAART) is associated with low level hepatotoxicity at therapy initiation, regardless of drug class or 
combination. 




Antiretroviral drug-related liver injury (ARLI) is 
defined by elevations in liver enzymes in serum, 
with alanine aminotransferase (ALT) 
characteristically greater than aspartate 
aminotransferase (AST). It is one of the greatest 
causes of treatment discontinuation in HIV-infected 
patients [1]. Its prevention and management is 
therefore very important among HIV-infected 
patients who are to be placed on highly active 
antiretroviral therapy (HAART) [2]. Till date, there 
has been broad variability in the criteria used in 
clinical studies to categorize the severity of 
hepatotoxicity. Some studies have utilized ALT 
parameters as minimal as two times the upper 
limits of normal [3] while others have employed an 
absolute threshold (e.g., >100 IU/ml), regardless of 
baseline liver function tests [4]. Surveys have 
reported an increased incidence of hepatic injury in 
HAART-treated patients and identified life-
threatening hepatotoxic events and end-stage liver 
disease in patients on antiretroviral [5]. 
With the widespread use of HAART and the 
availability of new antiretroviral medications, ARLI 
has gained prominent attention owing to its 
negative impact on clinical outcomes. Drug-
associated hepatotoxicity also creates an economic 
burden on already strained medical budgets, since 
additional visits and hospital admissions are often 
required for appropriate patient care and 
management [1]. Furthermore, antiretroviral drug 
discontinuation hampers maintenance of HIV 
suppression. The severity of ARLI may range from 
the absence of symptoms to liver decompensation, 
and the outcome can range from spontaneous 
resolution to liver failure and death [6]. 
In August 2003, Cameroon defined and included 
first and second line drug regimens in the national 
treatment guidelines, including different HIV-drug 
combinations based on WHO recommendations and 
in 2005, the number of people living with HIV was 
estimated at 505.000, among which 61% were  
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females. An estimated number of 108,000 
Cameroonians (0-49 years) were reported to be in 
need of antiretroviral therapy. This figure has been 
on the rise given that the number of people infected 
with the virus increased on daily basis and 
subsequently required treatment [7]. 
Several highly active antiretroviral therapy 
(HAART) regimens are hepatotoxic and the liver is 
one of the vital organs useful in the metabolism of 
these drugs as well as in detoxification. It is 
therefore important that the liver which is the main 
biochemical hub of the body be monitored and 
those HAART regimens that may be toxic to it 
identified so that changes or modifications can be 
made to enhance patient care. 
 
Materials and Methods 
Study Design  
A cross-sectional study that involved newly 
diagnosed HIV positive individuals who reported 
for treatment at the outpatient clinic of the Yaoundé 
central Hospital in Cameroon was done.  
Information extraction forms were used to collect 
data from patients’ files. 
 
Study area 
Yaoundé is the administrative capital of Cameroon 
with a population of 143000 inhabitants. It is 
centrally located and made up of immigrants from 
all the regions of Cameroon. The outpatient clinic of 
the Yaoundé Central Hospital is in the heart of the 
city. 
 
Study population  
The study was carried out on volunteer patients 
already diagnosed and confirmed to be HIV 
positive. Patients were made to understand that it 
was not a hospital obligation for them to participate 
in the research and neither was it a pre-requisite to 
accessing routine medical services. Written 
informed consent forms were distributed and 
explained to the participants one week prior to the 
beginning of the samples collection. Only HIV 
positive volunteers who returned their informed 
consent forms duly signed were recruited 
irrespective of their gender or clinical state of the 
disease. Only participants who were 20 years and 
above were recruited in the study 
 
Phases of the study 
The study was conducted for a period of three (3) 
years, from November 2006 to December 2009. 
Blood samples were collected in four (4) phases as 
follows. 
• Phase 1: in November 2006, before patients 
were placed on antiretroviral therapy 
• Phase 2: in November 2007 one year after 
commencement of therapy 
• Phase 3: in November 2008, two years after 
commencement of therapy 
• Phase 4: December 2009, final phase. 
Laboratory procedure              
About 4ml of blood samples were collected by 
venipuncture into labelled (coded) dry test tubes. 
After collection, samples were irreversibly de-linked 
from donor’s information except that concerning the 
age. Blood samples were allowed to coagulate after 
which they were centrifuged at 3000 rpm for 
5minutes to obtain sera. 
 
Measurement of ALT (SGPT) 
Measurement of ALT was done following a method 
that has been made according to the 2002 
International Federation of Clinical Chemistry 
(IFCC) protocol [8]. Commercial kits produced by 
HOSPITEX DIAGNOSTICS Ltd were used. The test 
was carried out using the monoreagent procedure. 
The working reagent was prepared by mixing 4 
volumes of reagent one (R1) in 1 volume of reagent 
two (R2). Mixed by inversion and stored away from 
any light sources at 2-8°C. 
The spectrophotometer was calibrated for ALT 
measurement. A series of labelled test tubes, i.e. 
Blank, normal control and patients from 1, 2….nth 









Patient 1ml 100ul 
 
The preparation was mixed and the first reading of 
absorbance was executed after 90 seconds. 
Incubating at 37°C, 3 other readings were 
performed at 60 seconds interval. The change in 
absorbance per minute was then calculated. 
The activities were obtained from the following 
calculations: 
340nm: Activity (U/L) = change in absorbance / 
min. x 1769. 
Normal values for ALT (SGPT) at 37°C: Women up 
to 34U/L. Men up to 45U/L. 
 
Measurement of AST (SGOT) 
 Measurement of AST was done following a method 
that has been made according to the 2002 
International Federation of Clinical Chemistry 
(IFCC) protocol [8]. Commercial kits produced by 
HOSPITEX DIAGNOSTICS Ltd were used. The test 
was conducted using the monoreagent procedure. 
 
The working reagent was prepared by adding the 
vial of reagent two (R2) in the vial of reagent one 
(R1). The reagent was then stored at 2-8°C away 
from any light sources. 
The spectrophotometer was calibrated for AST 
measurement. A series of labelled test tubes, i.e. 
Blank, normal control and patients from 1, 2….nth 
according to the number of samples to be analysed.  











Patient 1ml 100ul 
 
The preparation was mixed and the first reading of 
absorbance was executed after 90 seconds. Incubating 
at 37°C, 3 other readings were performed at 60 
seconds interval. The change in absorbance per 
minute was then calculated as follows: 
340nm: Activity (U/L) = Change in absorbance/ 
minute x 1769. 
 (Normal values for AST (SGOT):  Women up to 
31U/L and Men up to 35U/L).       
 
Statistical Analysis 
Statistical tests such as Chi-square and Pearson’s 
product moment correlation were used to test for the 
significance of the results obtained. 
 
Results 
Of the 150 patients who participated in this study, 81 
(54.0 %) showed a transaminitis with respect to AST 
at the final phase of the study, 77.78% (63/81) of 
whose AST levels only increased after initiation of 
HAART. 22.67% (34/150) presented with 
transaminitis with respect to ALT at the final phase, 
70.58% of whose ALT levels only increased at 
HAART initiation. Increase in AST levels was found 
to be is associated with an increase in ALT levels 
upon treatment (r = 0.58). 
Figure 1 and Figure 2 show the relationship between 
the mean concentration of transaminases (SGOT and 
SGPT) and the duration of treatment. There was a 
linear increase of SGOT mean concentration in blood 
over time (r=0.81).  
 
 
                   (r=0.81)  
Figure 1: The relationship between the mean concentration 
of SGOT and duration of treatment 
 
                               (r=0.99) 
Figure 2: The relationship between the mean  
concentration of SGPT and duration of treatment 
Also, there was a significant positive linear 
relationship between the concentration of 
transaminase (SGPT) with treatment duration 
(r=0.99).The level of transaminases concentration was 
found to be increasing over time.  
 
Tables 1 shows the age groups and AST levels among 
the 150 patients. The both transaminase levels were 
highest among the patients aged above 50 years. 
Table 2 shows the drug combinations and 
transaminase (AST and ALT) levels. Stocrin,Duovir 
was the combination showing the highest percentage 
of increased AST (55.17%) while LamivirS showed the 
highest percentage of increased ALT (35.29%).   
 













20-35 73 32 ( 21.33) 19 (26.02) 
36-50 57 29 (50.87) 13 (22.80) 
>50 20 14 (70) 8   (40) 
Total 150 75 (50) 40 (26.67) 
*percentage based on number of participant of the  








































































rug combination Total Number(%* showing 
high AST levels 
Number(%)* 
showing high ALT levels 
ZidolamN 24 9 (37.5) 6 (25) 
LamivirS 17 7 (41.18) 6 (35.29) 
Triomine 51 33 (64.7) 15 (29.41) 
Stocrin, 
Duovir 
58 32 (55.17) 7 (12.07) 
Total 150 81 (54.0) 34 (22.67) 
Table 2: Drug combinations and transaminase  (AST and ALT) levels 
*percentage based on number of participant using the same drug combination  X2= 5.78    P>0.05 
 
Discussion 
In 2004 Cameroon was still in the context of 
generalized HIV epidemic, with a prevalence of 5,5% 
of which 6,8% were women and 4,1% were  men. 
Groups identified to have high risk behaviours 
included mostly men and women in uniform,  
commercial sex workers, truck drivers and 
populations living along the Chad – Cameroon 
pipeline project area. Youths around 20 years of age 
were found to be the most  vulnerable. The major 
mode of transmission was through non – protected 
heterosexual activity, even if mother to child 
transmission remained a preoccupation [9], [8]. These 
are reasons why the study population sample 
included only individuals above.  
 
In the present study, the level of transaminases 
concentration was found to be increasing over time. 
These results tie with those obtained in a previous 
retrospective review of more than 10,000 adults living 
with AIDS in Boston, where researchers confirmed 
that long time antiretroviral therapy is associated 
with high rate of severe hepatotoxicity regardless of 
drug class or combination [5].  
 
In other studies, a different pattern of drug injury 
with nevirapine use has emerged, with onset of liver 
enzyme elevations occurring beyond 16 weeks of 
therapy, consistent with direct or idiosyncratic host-
mediated liver injury [10]. Rates of hepatotoxicity 
from various registration trials were ranged from 1% 
to 9.5%, but few patients have shown serious liver-
related outcomes [11]  
Also, based on the WHO toxicity scale, the greatest 
percentage of patients who presented with elevated 
levels of transaminases (76.81% for AST and 53.33% 
for ALT) were found to present with first degree 
hepatotoxicity which corresponds to low level liver 
toxicity. However, this does not tie with reports by 
spengler et al.[5] in which it was pointed out that 
longitudinal surveys have not only reported 
increased incidence of ARLI in patients but also 
identified life-threatening hepatotoxic events and 
end-stage liver disease in patients on antiretroviral 
therapy. The term hepatotoxicity may be misleading 
in the case of HIV drugs as some of the elevated liver 
enzymes may be due to other causes such as acute 
viral hepatitis, reactivation of chronic hepatitis B or C, 
alcohol ingestion as well as complementary drugs or 
medicines associated with HAART several of which 
have been noticed to be associated with clear-cut 
drug-induced hepatitis (DIH) for example used for 
the treatment of Tuberculosis [12]  
 
We have found transaminase levels to be highest 
among the patients aged above 50 years. Although 
this finding was not statistically significant, it was in 
accordance with that of spengler et al. [5], but did not 
tie with a more recent report[13] in which younger 
diabetic patients had a higher tendency to have 
elevated ALT compared to those over 65 years. Our 
study shows significant relationship between the age 
of the patient and the level of transaminases 
concentration. Other studies have indicated that 
certain co morbidities, such as chronic hepatitis B 
(HBV) or hepatitis C (HCV) infection, may predispose 
patients to ARLI [10]. Highly active antiretroviral 
therapy (HAART) was found to be associated with 
low level hepatotoxicity at initiation, regardless of 
drug class or combination. Elevated transaminases 
due to antiretroviral therapy was independent on 
patient’s age and increased levels of transaminases 
showed a significant positive linear relationship with 
increase in the duration of treatment. We therefore 
recommended that levels of transaminases should be 
followed up after initiation of antiretroviral therapy 
for all patients irrespective of their drug combination 
or age. The role of liver steatosis as a mechanism of, 
and as predisposing factor to anti retroviral drug-
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